{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:02:18Z","timestamp":1785852138405,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH Office of Research and Infrastructure Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00734-9","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:59:51Z","timestamp":1738007991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical use of a clinically-relevant scAAV9\/SUMF1 vector for the treatment of multiple sulfatase deficiency"],"prefix":"10.1038","volume":"5","author":[{"given":"Maximiliano","family":"Presa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-5548","authenticated-orcid":false,"given":"Rachel M.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somdatta","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4065-4541","authenticated-orcid":false,"given":"Lauren","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Tata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Alexandre","family":"Piec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6240-8621","authenticated-orcid":false,"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2502-1900","authenticated-orcid":false,"given":"Cathleen","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"734_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0092-8674(03)00348-9","volume":"113","author":"MP Cosma","year":"2003","unstructured":"Cosma, M. P. et al. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113, 445\u2013456 (2003).","journal-title":"Cell"},{"key":"734_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0092-8674(03)00347-7","volume":"113","author":"T Dierks","year":"2003","unstructured":"Dierks, T. et al. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C\u03b1-formylglycine generating enzyme. Cell 113, 435\u2013444 (2003).","journal-title":"Cell"},{"key":"734_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cell.2005.03.001","volume":"121","author":"T Dierks","year":"2005","unstructured":"Dierks, T. et al. Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. Cell 121, 541\u2013552 (2005).","journal-title":"Cell"},{"key":"734_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymgme.2020.06.005","volume":"130","author":"G Cappuccio","year":"2020","unstructured":"Cappuccio, G., Alagia, M. & Brunetti-Pierri, N. A systematic cross-sectional survey of multiple sulfatase deficiency. Mol. Genet. Metab. 130, 283\u2013288 (2020).","journal-title":"Mol. Genet. Metab."},{"key":"734_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/jmedgenet-2021-108061","volume":"59","author":"S Verheyen","year":"2022","unstructured":"Verheyen, S. et al. Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency. J. Med. Genet. 59, 957\u2013964 (2022).","journal-title":"J. Med. Genet."},{"key":"734_CR6","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/jimd.12298","volume":"43","author":"LA Adang","year":"2020","unstructured":"Adang, L. A. et al. Natural history of multiple sulfatase deficiency: retrospective phenotyping and functional variant analysis to characterize an ultra-rare disease. J. Inherit. Metab. Dis. 43, 1298\u20131309 (2020).","journal-title":"J. Inherit. Metab. Dis."},{"key":"734_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ymgme.2018.01.005","volume":"123","author":"R Ahrens-Nicklas","year":"2018","unstructured":"Ahrens-Nicklas, R. et al. Complex care of individuals with multiple sulfatase deficiency: clinical cases and consensus statement. Mol. Genet. Metab. 123, 337\u2013346 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"734_CR8","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1073\/pnas.0700382104","volume":"104","author":"C Settembre","year":"2007","unstructured":"Settembre, C. et al. Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. Proc. Natl. Acad. Sci. USA 104, 4506\u20134511 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"734_CR9","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/mtm.2016.2","volume":"3","author":"N Cl\u00e9ment","year":"2016","unstructured":"Cl\u00e9ment, N. & Grieger, J. C. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol. Ther. Methods Clin. Dev. 3, 16002 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"734_CR10","first-page":"Unit 4.17","volume":"Chapter 4","author":"SJ Gray","year":"2011","unstructured":"Gray, S. J. et al. Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Curr. Protoc. Neurosci. Chapter 4, Unit 4.17 (2011).","journal-title":"Curr. Protoc. Neurosci."},{"key":"734_CR11","doi-asserted-by":"publisher","first-page":"e137159","DOI":"10.1172\/JCI137159","volume":"131","author":"M Presa","year":"2021","unstructured":"Presa, M. et al. AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model. J. Clin. Investig. 131, e137159 (2021).","journal-title":"J. Clin. Investig."},{"key":"734_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/mt.2010.299","volume":"19","author":"C Spampanato","year":"2011","unstructured":"Spampanato, C. et al. Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol. Ther. 19, 860\u2013869 (2011).","journal-title":"Mol. Ther."},{"key":"734_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0009-8981(90)90339-T","volume":"187","author":"OP van Diggelen","year":"1990","unstructured":"van Diggelen, O. P. et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). Clin. Chim. Acta 187, 131\u2013139 (1990).","journal-title":"Clin. Chim. Acta"},{"key":"734_CR14","doi-asserted-by":"publisher","first-page":"e146286","DOI":"10.1172\/JCI146286","volume":"132","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. AAV9\/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease. J. Clin. Investig. 132, e146286 (2022).","journal-title":"J. Clin. Investig."},{"key":"734_CR15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1089\/hum.2010.245","volume":"22","author":"SJ Gray","year":"2011","unstructured":"Gray, S. J. et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143\u20131153 (2011).","journal-title":"Hum. Gene Ther."},{"key":"734_CR16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/gt.2011.130","volume":"19","author":"T Federici","year":"2012","unstructured":"Federici, T. et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 19, 852\u2013859 (2012).","journal-title":"Gene Ther."},{"key":"734_CR17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","volume":"19","author":"SJ Gray","year":"2011","unstructured":"Gray, S. J. et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058\u20131069 (2011).","journal-title":"Mol. Ther."},{"key":"734_CR18","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/sj.gt.3302134","volume":"10","author":"DM McCarty","year":"2003","unstructured":"McCarty, D. M. et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112\u20132118 (2003).","journal-title":"Gene Ther."},{"key":"734_CR19","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","volume":"8","author":"DM McCarty","year":"2001","unstructured":"McCarty, D. M., Monahan, P. E. & Samulski, R. J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248\u20131254 (2001).","journal-title":"Gene Ther."},{"key":"734_CR20","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.1073\/pnas.76.12.6496","volume":"76","author":"AL Horwitz","year":"1979","unstructured":"Horwitz, A. L. Genetic complementation studies of multiple sulfatase deficiency. Proc. Natl. Acad. Sci. USA 76, 6496\u20136499 (1979).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"734_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2013.04.001","volume":"106-107","author":"BD Semple","year":"2013","unstructured":"Semple, B. D., Blomgren, K., Gimlin, K., Ferriero, D. M. & Noble-Haeusslein, L. J. Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Prog. Neurobiol. 106-107, 1\u201316 (2013).","journal-title":"Prog. Neurobiol."},{"key":"734_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","volume":"9","author":"RM Bailey","year":"2018","unstructured":"Bailey, R. M., Armao, D., Nagabhushan Kalburgi, S. & Gray, S. J. Development of intrathecal AAV9 gene therapy for giant axonal neuropathy. Mol. Ther. - Methods Clin. Dev. 9, 160\u2013171 (2018).","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"734_CR23","doi-asserted-by":"publisher","first-page":"146832","DOI":"10.1016\/j.brainres.2020.146832","volume":"1739","author":"RM Bailey","year":"2020","unstructured":"Bailey, R. M., Rozenberg, A. & Gray, S. J. Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies. Brain Res. 1739, 146832 (2020).","journal-title":"Brain Res."},{"key":"734_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2012.101","volume":"20","author":"SJ Gray","year":"2013","unstructured":"Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J. & Jude Samulski, R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20, 450\u2013459 (2013).","journal-title":"Gene Ther."},{"key":"734_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1089\/hum.2013.005","volume":"24","author":"L Samaranch","year":"2013","unstructured":"Samaranch, L. et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 24, 526\u2013532 (2013).","journal-title":"Hum. Gene Ther."},{"key":"734_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1089\/hum.2011.200","volume":"23","author":"L Samaranch","year":"2012","unstructured":"Samaranch, L. et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23, 382\u2013389 (2012).","journal-title":"Hum. Gene Ther."},{"key":"734_CR27","doi-asserted-by":"crossref","unstructured":"Sorrentino, N. C. et al. New mouse models with hypomorphic SUMF1 variants mimic attenuated forms of multiple sulfatase deficiency. J. Inherit. Metab. Dis. 46, 335\u2013347 (2022).","DOI":"10.1002\/jimd.12577"},{"key":"734_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fcell.2020.00132","volume":"8,","author":"D Intartaglia","year":"2020","unstructured":"Intartaglia, D. et al. Retinal degeneration in MPS-IIIA mouse model. Front. Cell Dev. Biol. 8, 132 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"734_CR29","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1167\/iovs.15-17645","volume":"57","author":"K Kruszewski","year":"2016","unstructured":"Kruszewski, K., L\u00fcllmann-Rauch, R., Dierks, T., Bartsch, U. & Damme, M. Degeneration of photoreceptor cells in arylsulfatase G-deficient mice. Investig. Ophthalmol. Vis. Sci. 57, 1120\u20131131 (2016).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"734_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/13816810.2015.1028647","volume":"37","author":"J Wilkin","year":"2016","unstructured":"Wilkin, J., Kerr, N. C., Byrd, K. W., Ward, J. C. & Iannaccone, A. Characterization of a case of pigmentary retinopathy in sanfilippo syndrome type IIIA associated with compound heterozygous mutations in the SGSH gene. Ophthalmic Genet. 37, 217\u2013227 (2016).","journal-title":"Ophthalmic Genet."},{"key":"734_CR31","unstructured":"Hopwood, J. J. & Ballabio, A. Multiple sulfatase deficiency and the nature of the sulfatase family. in The Online Metabolic and Molecular Bases of Inherited Disease (eds. Valle, D. L., Antonarakis, S., Ballabio, A., Beaudet, A.L. & Mitchell, G. A.) (McGraw-Hill Education, 2019)."},{"key":"734_CR32","unstructured":"Scriver, C. R., Beaudet, A. L., Sly, W. S. & Valle, D. Metabolic and Molecular Basis of Inherited Diseases (McGraw Hill, 2001)."},{"key":"734_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.mt.6300012","volume":"15","author":"T Kurai","year":"2007","unstructured":"Kurai, T. et al. AAV1 mediated co-expression of formylglycine-generating enzyme and arylsulfatase a efficiently corrects sulfatide storage in a mouse model of metachromatic leukodystrophy. Mol. Ther. 15, 38\u201343 (2007).","journal-title":"Mol. Ther."},{"key":"734_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/hum.2015.170","volume":"27","author":"LK Winner","year":"2016","unstructured":"Winner, L. K. et al. A preclinical study evaluating AAVrh10-based gene therapy for sanfilippo syndrome. Hum. Gene Ther. 27, 363\u2013375 (2016).","journal-title":"Hum. Gene Ther."},{"key":"734_CR35","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1089\/hum.2013.238","volume":"25","author":"M Tardieu","year":"2014","unstructured":"Tardieu, M. et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial. Hum. Gene Ther. 25, 506\u2013516 (2014).","journal-title":"Hum. Gene Ther."},{"key":"734_CR36","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/hmg\/ddu727","volume":"24","author":"A Ribera","year":"2015","unstructured":"Ribera, A. et al. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. Hum. Mol. Genet 24, 2078\u20132095 (2015).","journal-title":"Hum. Mol. Genet"},{"key":"734_CR37","doi-asserted-by":"publisher","unstructured":"Garza, I. T., Eller, M. M., Holmes S. K., Schackmuth M. K., & Bailey R. M. Expression and distribution of rAAV9 intrathecally administered in juvenile to adolescent mice. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-024-00498-2 (2024).","DOI":"10.1038\/s41434-024-00498-2"},{"key":"734_CR38","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s10545-009-1275-9","volume":"32","author":"IVD Schwartz","year":"2009","unstructured":"Schwartz, I. V. D. et al. Clinical and biochemical studies in mucopolysaccharidosis type II carriers. J. Inherit. Metab. Dis. 32, 732\u2013738 (2009).","journal-title":"J. Inherit. Metab. Dis."},{"key":"734_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62536-4","volume":"10","author":"HS Yoo","year":"2020","unstructured":"Yoo, H. S. et al. Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinson\u2019s disease. Sci. Rep. 10, 5567 (2020).","journal-title":"Sci. Rep."},{"key":"734_CR40","doi-asserted-by":"publisher","first-page":"e164575","DOI":"10.1172\/JCI164575","volume":"133","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Intrathecal AAV9\/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies. J. Clin. Investig. 133, e164575 (2023).","journal-title":"J. Clin. Investig."},{"key":"734_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neuro.2024.02.001","volume":"101","author":"C Tyszkiewicz","year":"2024","unstructured":"Tyszkiewicz, C. et al. Absence of functional deficits in rats following systemic administration of an AAV9 vector despite moderate peripheral nerve and dorsal root ganglia findings: a clinically silent peripheral neuropathy. Neurotoxicology 101, 46\u201353 (2024).","journal-title":"Neurotoxicology"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00734-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00734-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00734-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T19:59:55Z","timestamp":1738007995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00734-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00734-9","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.M.B and S.J.G. received royalty income from Neurogene Inc. and Taysha Gene Therapies (World patent: WO2020223215A1, \u201cOptimized SUMF1 Genes and Expression Cassettes and Their Use\u201d). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}